利奈唑胺致血红蛋白减少的回顾性研究

Reduction of hemoglobin induced by linezolid therapy： a retrospective study

收集197例接受利奈唑胺治疗住院患者的临床资料,分析利奈唑胺所致Hb减少的情况及相关危险因素.利奈唑胺所致Hb减少的发生率为31.98％;Hb减少的患者与未减少的患者相比较年龄较大[（68±14）与（59±18）岁,P=0.000]、肌酐清除率（CCr）较低[（72±42）与（98±52） ml/min,P=0.000];多因素logistic回归分析结果显示,利奈唑胺相关Hb减少的危险因素包括年龄≥65岁、用药疗程≥15 d、CCr＜ 65 ml/min和基础Hb值＜95 g/L.

The medical records of 197 patients on linezolid therapy were collected retrospectively.The prevalence and risk factors for linezolid-induced reduction of hemoglobin were identified. The incidence of linezolid-induced reduction of hemoglobin was 31.98%. The patients with reduction of hemoglobin had older age [ （68 ± 14） vs. （ 59 ± 18 ） years, P = 0. 000 ] and lower creatinine clearance （CCr） [ （ 72 ± 42 ） vs. （98 ± 52） ml/min, P = 0. 000]. Multivariate logistic regression analysis showed that age ≥65 years, treatment duration ≥ 15 days, CCr 〈 65 ml/min and pre-treatment hemoglobin value 〈 95 g/L were significant risk factors for linezolid-induced reduction of hemoglobin.